How do you modify your adjuvant therapy course in a patient experiencing liver dysfunction within the first few months of starting CDK4/6i?

We will adhere to the CTCAE grading system. Most of these patients do well with dose reduction and interruption. If persistent grade 2/3, will likely change to an alternate CDK agent and evaluate whether it solves LFT issues.